S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:BVXVBIONDVAX PHARMA/S Stock Price, Forecast & News

$38.49
-0.94 (-2.38 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$38.24
Now: $38.49
$38.85
50-Day Range
$19.27
MA: $33.87
$51.10
52-Week Range
$5.20
Now: $38.49
$62.00
Volume40,224 shs
Average Volume81,186 shs
Market Capitalization$437.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($2.88) per share

Profitability

Net Income$-31,600,000.00

Miscellaneous

Employees14
Market Cap$437.02 million
Next Earnings Date8/26/2020 (Estimated)
OptionableNot Optionable
$38.49
-0.94 (-2.38 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

How has BIONDVAX PHARMA/S's stock been impacted by COVID-19 (Coronavirus)?

BIONDVAX PHARMA/S's stock was trading at $6.5350 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BVXV shares have increased by 489.0% and is now trading at $38.49.
View which stocks have been most impacted by Coronavirus
.

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020.
View our earnings forecast for BIONDVAX PHARMA/S
.

How were BIONDVAX PHARMA/S's earnings last quarter?

BIONDVAX PHARMA/S (NASDAQ:BVXV) posted its quarterly earnings results on Tuesday, June, 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.07.
View BIONDVAX PHARMA/S's earnings history
.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

News headlines about BVXV stock have trended very positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about BIONDVAX PHARMA/S
.

Are investors shorting BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 19,300 shares, an increase of 116.9% from the June 30th total of 8,900 shares. Based on an average trading volume of 125,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.3% of the shares of the company are short sold.
View BIONDVAX PHARMA/S's Short Interest
.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), Alibaba Group (BABA), Exelixis (EXEL), Agilent Technologies (A), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX), NVIDIA (NVDA) and Protalix Biotherapeutics (PLX).

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the following people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.

When did BIONDVAX PHARMA/S IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

Who are BIONDVAX PHARMA/S's major shareholders?

BIONDVAX PHARMA/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.10%) and UBS Group AG (0.02%).

Which institutional investors are buying BIONDVAX PHARMA/S stock?

BVXV stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and UBS Group AG.

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $38.49.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $437.02 million. The company earns $-31,600,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is www.biondvax.com.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.